Cyclacel Pharmaceuticals (CYCC) Competitors $7.36 -0.33 (-4.23%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. IRD, STRO, CVM, RPTX, GANX, APLT, LIMN, BYSI, GNTA, and PRLDShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Opus Genetics (IRD), Sutro Biopharma (STRO), CEL-SCI (CVM), Repare Therapeutics (RPTX), Gain Therapeutics (GANX), Applied Therapeutics (APLT), Liminatus Pharma (LIMN), BeyondSpring (BYSI), Genenta Science (GNTA), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Its Competitors Opus Genetics Sutro Biopharma CEL-SCI Repare Therapeutics Gain Therapeutics Applied Therapeutics Liminatus Pharma BeyondSpring Genenta Science Prelude Therapeutics Opus Genetics (NASDAQ:IRD) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment. Is IRD or CYCC more profitable? Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Opus Genetics' return on equity of -384.33% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-377.89% -384.33% -148.90% Cyclacel Pharmaceuticals N/A -723.64%-145.51% Do institutionals & insiders have more ownership in IRD or CYCC? 15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 6.6% of Opus Genetics shares are owned by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings & valuation, IRD or CYCC? Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$10.99M6.84-$57.53M-$1.92-0.65Cyclacel Pharmaceuticals$40K412.44-$11.21M-$839.58-0.01 Does the media prefer IRD or CYCC? In the previous week, Opus Genetics had 4 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 5 mentions for Opus Genetics and 1 mentions for Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 1.00 beat Opus Genetics' score of 0.74 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Opus Genetics Positive Cyclacel Pharmaceuticals Positive Do analysts recommend IRD or CYCC? Opus Genetics currently has a consensus price target of $7.33, indicating a potential upside of 484.33%. Given Opus Genetics' stronger consensus rating and higher possible upside, research analysts plainly believe Opus Genetics is more favorable than Cyclacel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, IRD or CYCC? Opus Genetics has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. SummaryCyclacel Pharmaceuticals beats Opus Genetics on 9 of the 16 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.50M$3.09B$5.75B$9.85BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-0.0120.8882.7926.52Price / Sales412.44369.93499.49162.43Price / CashN/A43.5325.7028.92Price / Book4.558.0310.786.50Net Income-$11.21M-$53.35M$3.28B$266.34M7 Day Performance-5.82%-1.05%-0.42%-1.25%1 Month Performance-24.92%5.84%6.47%3.30%1 Year Performance-97.10%10.76%49.47%23.59% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals1.4063 of 5 stars$7.37-4.2%N/A-97.0%$16.50M$40K-0.0114Positive NewsShort Interest ↓Gap DownIRDOpus Genetics1.9675 of 5 stars$1.22+2.5%$7.33+501.1%N/A$73.09M$10.99M-0.6414News CoveragePositive NewsGap UpSTROSutro Biopharma3.7955 of 5 stars$0.86-4.3%$4.47+421.1%-76.9%$72.66M$62.04M-0.34240Positive NewsCVMCEL-SCI0.4026 of 5 stars$10.43+12.0%N/A-63.1%$71.78MN/A-21.7343Short Interest ↑Gap UpRPTXRepare Therapeutics3.4826 of 5 stars$1.67+0.6%$4.50+169.5%-38.8%$71.74M$53.48M-0.65180News CoverageGANXGain Therapeutics2.8402 of 5 stars$1.99+5.9%$7.80+292.0%+84.6%$71.54M$50K-3.1620APLTApplied Therapeutics4.1338 of 5 stars$0.49-3.6%$6.10+1,138.1%-91.3%$70.96M$460K-1.0930Positive NewsLIMNLiminatus PharmaN/A$2.71-1.8%N/AN/A$70.50MN/A0.00N/AGap DownBYSIBeyondSpringN/A$1.72-4.4%N/A-5.7%$69.37M$1.75M0.0080News CoveragePositive NewsGNTAGenenta Science2.6839 of 5 stars$3.93+3.3%$25.00+536.9%-9.3%$68.78MN/A0.007Gap DownPRLDPrelude Therapeutics3.618 of 5 stars$1.21-7.6%$4.00+230.6%-76.1%$68.49M$7M-0.74120 Related Companies and Tools Related Companies Opus Genetics Competitors Sutro Biopharma Competitors CEL-SCI Competitors Repare Therapeutics Competitors Gain Therapeutics Competitors Applied Therapeutics Competitors Liminatus Pharma Competitors BeyondSpring Competitors Genenta Science Competitors Prelude Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
